New Key Statistics Module, Z-Score and F-Score
NAS:VCYT Key Ratios
| Market Cap $ M | 3,284.76 |
| Enterprise Value $ M | 2,839.64 |
| P/E(ttm) | 28.98 |
| PE Ratio without NRI | 19.46 |
| Forward PE Ratio | 30.34 |
| Price/Book | 2.37 |
| Price/Sales | 5.92 |
| Price/Free Cash Flow | 20.03 |
| Price/Owner Earnings | 26.46 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 561.00 |
| EPS (TTM) $ | 1.41 |
| Beneish M-Score | -2.53 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | 155.60 |
| EV-to-EBIT | 24.48 |
| EV-to-EBITDA | 20.75 |
| PEG | -- |
| Shares Outstanding M | 80.39 |
| Net Margin (%) | 20.37 |
| Operating Margin % | 19.34 |
| Pre-tax Margin (%) | 20.65 |
| Quick Ratio | 8.80 |
| Current Ratio | 9.16 |
| ROA % (ttm) | 8.13 |
| ROE % (ttm) | 8.78 |
| ROIC % (ttm) | 11.00 |
| Dividend Yield % | -- |
| Altman Z-Score | 20.86 |
VCYT Number of Guru Trades
VCYT Volume of Guru Trades
Gurus Latest Trades with NAS:VCYT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:VCYT is held by these investors
Total 4
Veracyte Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:VCYT
Artisan Mid Cap Fund
Bearish
2026 Q3
ARTMX APDMX APHMX MCommentary 0726 vR
What the manager wrote
Veracyte is a molecular diagnostics company focused on genomic testing that helps physicians make more informed treatment decisions and reduce unnecessary procedures. Recent results were mixed, with continued strength in Afirma® offset by a modest Decipher® shortfall following changes to prostate cancer treatment guidelines for low-risk patients. We trimmed the position as questions around Decipher® growth are likely to persist until newer product launches, such as Prosigna®, become more meaningful contributors. We continue to monitor the long-term opportunity.
News about NAS:VCYT
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers